Introduction
Streptococcus pneumoniae remains the most common cause of community-acquired pneumonia.
1 Nasopharyngeal carriage of this pathogen is common. It forms part of the normal flora of the nasopharynx and is found in approximately one-third of nasopharyngeal cultures of healthy children. 2, 3 Carriage of the same serotype can persist for months, especially in young infants.
Pneumococci are usually susceptible to penicillins, macrolides and cephalosporins in vitro. 4 However, since the identification of the first penicillin-resistant isolates in Australia and Papua New Guinea in the 1970s, 5 the prevalence of resistant pneumococci has increased steadily in Western and Eastern Europe, the Middle East and many other parts of the world. 6, 7 For example, in Israel, 69% of S. pneumoniae isolates are susceptible to penicillin, 30% have intermediate resistance and 1% are penicillin resistant (R. Dagan, Ben-Gurion University of the Negev, Israel; personal communication).
In order to gain an accurate view of emerging resistance patterns, regular monitoring and adherence to a standard methodology, such as that recommended by the NCCLS, 8 is necessary. The observation of increased incidence of resistance to one or more antibiotics frequently necessitates reconsideration of empirical therapy for local and systemic pneumococcal infections.
The Chaim Sheba Medical Centre is a teaching hospital with 1200 paediatric and adult patients. This study reports the susceptibility test results for 105 clinical isolates of S. pneumoniae collected over a 1 year period in this centre.
Materials and methods
In total, 105 clinical isolates of S. pneumoniae (derived from bacteraemia and pneumonia cases during [1995] [1996] were selected for analysis. The strains were selected randomly with no preference for susceptibility pattern.
The MICs were determined using the NCCLS guidelines for agar dilution susceptibility testing, 8 outlined as follows: Mueller-Hinton agar was prepared according to the manufacturer's instructions (Difco Laboratories, Detroit, MI, USA). The agar was autoclaved and allowed to cool to 50°C in a water bath before adding the antimicrobial agents and 5% lysed horse blood.
Four to five colonies from an overnight growth plate were inoculated into 2 mL Brain Heart Infusion broth, adjusted to a concentration of 10 7 cfu/mL and incubated for 5 h at 35°C. A sample was placed in a Cathra replicator seed block (AutoMed Inc., Arden Hills, MN, USA). Plates containing antimicrobial agents were inoculated (10 4 cfu/spot) using a multipoint inoculator. The plates were incubated in an atmosphere of 5% CO 2 at 35°C for 24 h. The MIC was recorded as the lowest concentration of the antimicrobial agent that inhibited bacterial growth.
Results and discussion
The number of clinical isolates of S. pneumoniae obtained each year from blood (mean 57, range 52-59) and sputum samples (mean 45, range 35-49) in the period 1990-1996 remained relatively constant apart from a fall in the number of isolates from sputum samples (35) obtained in 1991.
The results of this local survey also showed that there was a constant tendency towards a decreasing rate of penicillin susceptibility among S. pneumoniae isolates in the Sheba Medical Centre from 97% in 1990 to 85% during the study period 1995-1996. The MICs of the antimicrobial agents against the S. pneumoniae isolates are presented in the Table. The isolates were susceptible to levofloxacin (MIC 50/90 0.5 mg/L), ofloxacin (MIC 50/90 0.5 mg/L) and sparfloxacin (MIC 50/90 0.25 mg/L). However, some isolates had reduced susceptibility to ciprofloxacin, amoxycillin, cefuroxime and cefepime (Table) . All the isolates had an identical sensitivity to levofloxacin (MIC 0.5 mg/L).
Based on NCCLS breakpoints the cumulative susceptibility of the S. pneumoniae isolates to the agents tested is shown in the Figure. Overall, approximately 85% were susceptible to amoxycillin and other -lactam antibiotics. The proportion of isolates susceptible to ofloxacin was 100% (NCCLS breakpoint 2 mg/L), 90% to ciprofloxacin (NCCLS breakpoint 1 mg/L) and 100% to levofloxacin (NCCLS breakpoint 2 mg/L) and sparfloxacin (breakpoint 0.5 mg/L).
These results brought into question the appropriateness of current antibiotic treatment practices in our centre. At the time of this survey, amoxycillin was used as first-line therapy, with cefuroxime as second line. However, the susceptibility pattern observed in this study shows the emergence of strains resistant to both these drugs. In contrast, S. pneumoniae isolates tested were mostly susceptible to the fluoroquinolone antibiotics. In particular, all the isolates were susceptible to levofloxacin, ofloxacin and sparfloxacin. However, clinical data are required to support these in-vitro findings. Currently, vancomycin is considered to be the drug of choice for the treatment of invasive disease caused by S. pneumoniae fully resistant to -lactam agents. Dark et al., 9 in a comparative study of ofloxacin and cefaclor in lower respiratory tract infections (LRTIs), reported a clinical success rate of 88% for ofloxacin compared with 81% for cefaclor. The bacteriological eradication rate for ofloxacin was 85%. Kahn 10 assessed the efficacy of ofloxacin in the treatment of bacterial pneumonia and concluded that fluoroquinolones have good activity against both typical and atypical LRTI pathogens. Moreover, he reported an eradication rate of 96% for S. pneumoniae and good pharmacological parameters such as penetration of the drug into polymorphonuclear neutrophils, lung tissue and sputum.
The newer fluoroquinolones show good in-vitro activity against S. pneumoniae. [11] [12] [13] [14] George & Morrissey 11 reported that levofloxacin, the active L-isomer of ofloxacin, was the most potent of the fluoroquinolones tested against S. pneumoniae, and compared with cefotaxime levofloxacin was less active against penicillin-susceptible strains but more active against penicillin-resistant strains. In addition, levofloxacin has been shown to be effective against S. pneumoniae in a number of clinical studies including pneumonia, acute exacerbation of chronic bronchitis and sinusitis. [15] [16] [17] The clinical effectiveness of sparfloxacin has also been demonstrated in numerous studies. the newer fluoroquinolones show high in-vitro activity against S. pneumoniae, and some of them have demonstrated clinical efficacy, there is, at present, insufficient clinical data to support the routine treatment of pneumococcal bacteraemia with these drugs. Our results, however, suggest that further clinical investigation of the newer fluoroquinolones for this indication is warranted.
